Adap­ti­m­mune los­es $3B biobucks pact with Genen­tech

Roche’s Genen­tech has bro­ken off its col­lab­o­ra­tion and li­cense agree­ment on off-the-shelf T cell ther­a­pies with Adap­ti­m­mune.

The pull­back means Adap­ti­m­mune could

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.